Breaking News, Collaborations & Alliances

Amaran Biotech, Nippon Fine Chemical Sign MOU

Amaran Biotech will utilize its aseptic filling line and CDMO services to support Nippon Fine Chemical’s production of nanoparticle-based drugs.

Author Image

By: Charlie Sternberg

Associate Editor

Amaran Biotechnology Inc., a subsidiary of OBI Pharma specializing in Contract Development and Manufacturing Organization (CDMO) services for next-generation pharmaceuticals, has signed a Memorandum of Understanding (MOU) with Nippon Fine Chemical Co., Ltd., and its Taiwan subsidiary, Zillion Fine Chemicals International Co., Ltd. The three parties aim to deepen collaboration in the field of nanoparticle-based drug CDMO manufacturing while expanding their presence in Taiwan, Japan, and internati...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters